Small Molecule Compounds Modulating ApoA-I Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for increasing ApoA-I levels, such as recombinant ApoA-I or peptides mimicking ApoA-I, face challenges with stability, delivery, and in vivo half-life, while naturally occurring polyphenols like resveratrol have poor bioavailability and inconclusive clinical benefits for cardiovascular disease treatment.
Innovation Solution
Development of novel compounds, represented by Formulas I and II, which are administered to mammals to therapeutically regulate ApoA-I expression, potentially offering improved pharmacological properties over natural polyphenols by modulating ApoA-I transcription and increasing HDL-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant ApoA-I or peptides mimicking ApoA-I are used to increase ApoA-I levels, then ApoA-I levels are improved, but stability and in vivo half-life are worsened
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that do not directly replace ApoA-I but instead activate endogenous ApoA-I production through PPARĪ± receptor mediation. This indirect approach avoids the stability issues of recombinant proteins while achieving therapeutic ApoA-I level increases
Solution Approach 2:
The invention enables the body's own cells to produce ApoA-I through activation of endogenous gene expression by small molecule compounds. This self-service mechanism eliminates the need for external protein administration and leverages the body's natural production systems, ensuring proper stability and half-life characteristics
2Reliability
If naturally occurring polyphenols like resveratrol are used to treat cardiovascular disease, then potential therapeutic effects are achieved, but bioavailability is worsened and clinical benefits remain inconclusive
Solution Approach 1:
The patent employs small molecule compounds with optimized chemical structures and pharmacological properties that overcome the poor bioavailability of natural polyphenols. These compounds exhibit improved absorption, metabolism, and stability parameters while maintaining or enhancing the desired therapeutic effect on ApoA-I production
Data Source
AI summary
The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.